|Type||Kommanditgesellschaft auf Aktien with Societas Europaea as partner with unlimited liability (FWB: FRE)|
|Headquarters||Bad Homburg, Germany|
|Key people||Ulf M. Schneider (CEO and chairman of the management board), Gerd Krick (Chairman of the supervisory board)|
|Products||Kidney dialysis, infusion pumps, drugs, hospitals, medical care|
|Revenue||€16.522 billion (2011)|
|Operating income||€2.418 billion (2010)|
|Profit||€770 million (2011)|
|Total assets||€23.58 billion (end 2010)|
|Total equity||€8.844 billion (end 2010)|
|Employees||149,351 (end 2011)|
Fresenius SE & Co. KGaA is a German diversified medical equipment company based in Bad Homburg, Germany. The Fresenius Group provides products and services for dialysis, hospitals as well as inpatient and outpatient medical care. In addition, the company focuses on hospital management as well as on engineering and services for medical centers and other health care facilities.
Fresenius consists of four business segments, Fresenius Medical Care (a publicly traded company of which Fresenius owns 36%), Fresenius Helios, Fresenius Kabi and Fresenius Vamed. With activities in about 100 countries, it has more than 137,000 employees.
Another arm of Fresenius Kabi is Fresenius Kabi Oncology Plc. It produces generics of intravenous oncology products such as Paclitaxel, Irinotecan, Oxaliplatin, Gemcitabine, Cytarabine, Carboplatin, Topotecan, Docetaxel and Epirubicin.
Fresenius owns the Helios Kliniken, which has more than 60 hospitals and more than 18,500 beds, treating over 2 million patients annually. The hospital operator is one of the biggest providers of inpatient and outpatient care in Germany.
The North American branch of Fresenius Medical Care is headquartered in Waltham, Massachusetts.
The company was founded by Eduard Fresenius (1874–1946) in 1912.
On July 16, 2007, the company completed its conversion from an Aktiengesellschaft (AG - German public limited company) to a Societas Europaea, the European Union-wide equivalent. The company changed its legal status once again on January 28, 2011, becoming a Kommanditgesellschaft auf Aktien (KGaA - German partnership limited by shares) with a Societas Europaea as a partner with unlimited liability (SE & Co. KGaA).
In 2012 a paper was published raising concerns regarding the use of hydroxyethyl starch in sepsis. Fresenius Kabi, who makes the product, has threatened to bring legal action against the author, Anders Perner, as they disagree with the results. The academic community has raised concerns regarding this sort of behavior by a corporation.
- "Annual Report 2011". Fresenius. Retrieved 7 February 2012.
- "Annual Results 2010". Fresenius. Retrieved 24 February 2011.
- Fresenius SE (2007-07-16). "Fresenius completes conversion into a European Company (SE)". Retrieved 2007-08-12.
- "Fresenius successfully completes share conversion and change of legal form - First trading day of Fresenius SE & Co. KGaA shares January 31, 2011". Fresenius. 28 January 2011. Retrieved 24 February 2011.
- Perner, A; Haase, N; Guttormsen, AB; Tenhunen, J; Klemenzson, G; Åneman, A; Madsen, KR; Møller, MH; Elkjær, JM; Poulsen, LM; Bendtsen, A; Winding, R; Steensen, M; Berezowicz, P; Søe-Jensen, P; Bestle, M; Strand, K; Wiis, J; White, JO; Thornberg, KJ; Quist, L; Nielsen, J; Andersen, LH; Holst, LB; Thormar, K; Kjældgaard, AL; Fabritius, ML; Mondrup, F; Pott, FC; Møller, TP; Winkel, P; Wetterslev, J; 6S Trial, Group; Scandinavian Critical Care Trials, Group (2012 Jul 12). "Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.". The New England Journal of Medicine 367 (2): 124–34. doi:10.1056/NEJMoa1204242. PMID 22738085.
- Wojcik, Jeppe (July 24, 2012). "Pharma giant threatens Danish scientist". ScienceNordic. Retrieved 13 August 2012.
- Jonathan Gould and Ludwig Burger (13 September 2013). "Rhoen-Klinikum to sell hospitals to Fresenius in $4 billion deal". Reuters.
- Kamp, Michael / Neumann, Florian: Fresenius – 100 Years. Munich: August Dreesbach Verlag, 2012. ISBN 978-3-940061-84-3.